CRC.10 study recruitment Wednesday, April 15, 2026 Congratulations to Dr. Connor Wells who is a new investigator enrolling patients to the CRC.10 study at Alberta Health's Arthur J.E. Child Comprehensive Cancer Centre.Dr. Wells is a medical oncologist focusing on the treatment of genitourinary and gastrointestinal cancers. He is originally from Calgary but has completed his medical training at Queen’s University and the University of British Columbia. He has a Master of Science from the University of Oxford and spent two years in London, UK working in clinical trials. He has also completed the Clinician Investigator Program through the University of British Columbia. His research interests are currently focused on understanding and optimizing barriers to clinical trial participation, treatment of cancers in young adults, and new cancer treatments. "Dr. Wells participated as a new investigator by accruing two GI patients for the first time last month! The committee is delighted to have him as part of our investigator community at CCTG and hope that this will be the beginning of a mutually rewarding collaboration." Dr Charlene Gill, Chair of the GI Site Committee at CCTG.CRC10 (NCT05174169) (NRG-GI008) Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)Researchers are leveraging new technology to identify tiny amounts of cancer cell DNA in the blood, circulating tumour DNA (ctDNA), as an indicator of the presence of otherwise undetectable numbers of residual colon cancer cells after surgical removal of the main tumour. The goal of the research is to determine whether and how using this information about the presence or absence of ctDNA may allow them to make better decisions about what kind and amount of chemotherapy to recommend to patients after surgery for colon cancer.For CRC10 patient information >For CRC10 members information .CRC10 (NRG-GI008) is an intergroup study led by NRG Oncology NCT0517416 >
